BUZ INVESTORS PRESS RELEASE Debenture Offering Aurora Cannabis Inc. (the "Company" or "Aurora") (TSXV: ACB) (OTCQX: ACBFF) (

Aurora and WeedMD Announce Strategic Agreement

Aurora and WeedMD Announce Strategic Agreement

 

Arrangement to Provide Additional Product Supply to Aurora, Growth Acceleration for WeedMD

Strategic Agreement    Aurora Cannabis Inc. (the "Company" or "Aurora") (TSX-V: ACB) (OTCQX: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) and WeedMD Inc. ("WeedMD") (TSX-V: WMD) are pleased to announce that the companies have entered into a strategic relationship

BUZ INVESTORS   PRESS RELEASE Strategic Agreement    Aurora Cannabis Inc. (the “Company” or “Aurora”) (TSX-V: ACB) (OTCQX: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) and WeedMD Inc. (“WeedMD”) (TSX-V: WMD) are pleased to announce that the companies have entered into a strategic relationship whereby WeedMD will provide wholesale dried medical cannabis to Aurora, and Aurora will provide best in class patient education services for WeedMD through its cannabis counselling and outreach unit CanvasRx.

WeedMD’s commitment under the agreement is to wholesale product to Aurora for demand above and beyond WeedMD’s own patient requirements. Pursuant to the agreement, WeedMD has made an initial sale to Aurora out of inventoried product, while ensuring that its retained supply is such that current and future patient needs can be met.

Aurora, in turn, will assist WeedMD with its patient education and outreach program through the Company’s CanvasRx unit. This makes available to WeedMD expert knowledge and experience in patient counselling, outreach and interaction, accelerating WeedMD’s ability to engage with its growing customer base.

“This is a win-win relationship benefiting both companies,” said Terry Booth, Aurora CEO. “We are always looking to expand our product offering, both in terms of quantity for sale and new strains, but we will only do so if we are highly confident that the new products meet the industry-leading Aurora Standard. We have been following WeedMD closely since we first met with their team three years ago, and are impressed with their rigorous commitment to Good Production Practices. We therefore believe WeedMD’s products will make a strong addition to our product portfolio, and we look forward to building a deeper relationship as both companies continue to expand.”




Strategic Agreement

Bruce Dawson-Scully, CEO of WeedMD, added, “This relationship represents a cost-effective opportunity to accelerate our commercial development, as we become part of the growing medical market and prepare for future adult consumer use. We are very excited to be entering into a strategic relationship with one of the world’s leading cannabis companies, and benefit from their brand recognition, as well as their counselling, and sales and marketing know-how. Finally, the collaboration with Aurora’s CanvasRx, which has been an extremely valuable resource for medical cannabis patients across the country, will help us generate an important presence in the market.”

About Aurora

Aurora’s wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed producer of medical cannabis pursuant to Health Canada’s Access to Cannabis for Medical Purposes Regulations (“ACMPR”). The Company operates a 55,200 square foot, state-of-the-art production facility in Mountain View County, Alberta, and is currently constructing a second 800,000 square foot production facility, known as “Aurora Sky”, at the Edmonton International Airport, and has acquired, and is undertaking completion of, a third 40,000 square foot production facility in Pointe-Claire, Quebec, on Montreal’s West Island. In addition, the company is the cornerstone investor with a 19.9% stake in Cann Group Limited, the first Australian company licensed to conduct research on and cultivate medical cannabis, as well as owns Pedanios, a leading wholesale importer, exporter, and distributor of medical cannabis in the European Union (“EU”), based in Germany. Aurora’s common shares trade on the TSX-V under the symbol “ACB”.

About WeedMD

WeedMD Inc. is a licensed producer of medical cannabis pursuant to the Access to Cannabis for Medical Purposes Regulations (ACMPR). WeedMD operates a 26,000 square foot, scalable production facility in Aylmer, Ontario with four acres of property for future expansion. WeedMD is focused on providing consistent, quality medicine to the long-term care and assisted living markets in Canada through its comprehensive platform developed exclusively for that industry. WeedMD is dedicated to educating healthcare practitioners and furthering public understanding of the role medical cannabis can play as a viable alternative to prescription medication in relieving a variety of chronic medical conditions and illnesses.

Like up on FACEBOOK


logo



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )




BUZ INVESTORS PRESS RELEASE Debenture Offering Aurora Cannabis Inc. (the "Company" or "Aurora") (TSXV: ACB) (OTCQX: ACBFF) (

Aurora and Radient Technologies Announce Positive Results from Research Joint Venture

|Chart | Calendar   | TRADE NOW | Aurora

Aurora and Radient Technologies Announce Positive Results from Research Joint Venture

 

Collaboration Validates that Radient’s Proprietary Extraction Technology Offers Superior Cannabinoid Extraction Efficiency and Significantly Higher Throughput than Conventional Processes

BUZ INVESTORS PRESS RELEASE   Positive Results from Research   Aurora Cannabis Inc. (the “Company” or “Aurora”) (TSXV: (ACB) (OTCQX: (ACBFF) (Frankfurt: 21P; WKN: A1C4WM) and Radient Technologies (“Radient”) (TSX-V: RTI) are pleased to announce the successful completion of their Joint Venture Research Activity (“JV”), confirming the effectiveness of Radient’s proprietary MAPTM Technology and associated continuous flow design for extracting cannabinoids from dried cannabis.

On December 14, 2016, Radient and Aurora executed a Memorandum of Understanding (“MOU”) to evaluate an exclusive partnership for the Canadian market with regard to the joint development and commercialization of superior and standardized cannabinoid extracts. The first element of the collaboration was the execution of a joint research project to assess the feasibility of applying Radient’s proprietary technology for the extraction of cannabinoids from cannabis, including the establishment of parameters of extraction yields, recovery rates of available cannabinoids, purity of the extracts obtained, and the determination of cannabinoids and terpene profiles. The feasibility study also included an assessment of the potential processing throughput achievable using Radient’s large-scale continuous-flow MAPTM extractor, based upon established extraction conditions.

Positive Results from Research

 

Radient’s MAPTM technology enables precise control of temperature and extraction time of continuously flowing material, both of which affect purity and extract profile.  This careful control of extraction parameters and product quality is something that is impossible to achieve at large scale using conventional methods.  Extremely high (quantitative) recovery of available cannabinoids is possible in extraction times that are shaved from hours to minutes.

The study was conducted in two phases: bench-scale screening experiments of MAPTM extraction conditions; and scaled-up experiments under preferred extraction conditions. The analytical data from the research project were verified and confirmed by Anandia Labs Inc., a leading Canadian independent cannabis testing laboratory.

Key findings:

  • Consistently high extraction efficiencies of up to 98% (quantitative recovery) were observed compared to 80 – 85% typical for conventional technologies;
  • Exceptionally short processing times of as little as five minutes were achieved, as compared to approximately 6 hours for currently used commercial technologies;
  • Consistently high purity levels were observed for the extracts produced, at least on par with those achieved using conventional methods;
  • The research data indicate that throughputs in excess of 1,500 kg per day can potentially be achieved using Radient’s proprietary large-scale continuous-flow MAPTM extractor, many times higher than what can be achieved using conventional methods;
  • Replication of this technology in other jurisdictions on a larger or smaller scale is feasible;
  • Extract profiles obtained during the project show near full preservation of cannabinoid and terpene profiles in the extracts;

Based on the positive results of the study Radient and Aurora have agreed to negotiate an exclusive development and commercialization agreement for the use of Radient’s technology, and to continue their exclusive Joint Venture for additional scientific Research and Development of cannabis and hemp products.

“These results clearly validate the game changing nature of Radient’s technology for the cannabis sector,” said Terry Booth, CEO of Aurora. “The ability to produce high-purity concentrates at very high throughputs, while preserving terpene profiles, will provide a substantial competitive advantage for us in addressing the high-growth concentrates market. We see a number of factors that will require a significant expansion of production capacity for extracts, including our own expanding national and international footprint, the continued strong growth of the medical market in Canada, Germany and Australia, and the commencement of Canadian adult usage sales anticipated for July of 2018. The exclusive use of Radient’s technology positions us as the clear leader in this field, which we believe will enable Aurora to capture a significant share of this high-margin market.”

Booth concluded, “Aurora is very pleased to be a significant shareholder of Radient, and as part of our partnership with them, plan on continuing to hold a significant position in Radient.”

Radient’s CEO, Denis Taschuk, stated, “The positive outcome of the joint research project is a key milestone in the commercial development of Radient. With these results in our pocket, we are now able to commercialize our technology in what has become the fastest growing sector of the North American economy.  We are very pleased to embark on this journey with Aurora, who have proven to embrace innovation and who have developed one of the strongest brands within the cannabis industry, both in Canada and internationally.”

Radient also announces that, pursuant the terms of the convertible debenture issued to Aurora on February 13, 2017, Radient will make the first quarterly interest payment of $50,000 to Aurora through the issuance of additional units to Aurora (“Units”).  Each Unit consisting of one common share and one common share purchase warrant.

The interest payment was payable to Aurora on May 13, 2017 and the conversion price for the issuance of the Units is $0.48 being Radient’s closing trading price on Friday May 12, 2017.  Based on this conversion price, Radient will issue 104,167 common shares and 104,167 common share purchase warrants to Aurora in satisfaction of the interest payment.  Each common share purchase warrant will entitle Aurora to acquire one additional common share of Radient at an exercise price of $0.48 per share. The issuance of the Units to Aurora is subject to final approval of the TSX Venture Exchange and the Units will be subject to a four month hold period.

About Aurora

Aurora’s wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed producer of medical cannabis pursuant to Health Canada’s Access to Cannabis for Medical Purposes Regulations (“ACMPR”). The Company operates a 55,200 square foot, state-of-the-art production facility in Mountain View County, Alberta, and is currently constructing a second 800,000 square foot production facility, known as “Aurora Sky”, at the Edmonton International Airport, and has acquired, and is undertaking completion of, a third 40,000 square foot production facility in Pointe-Claire, Quebec, on Montreal’s West Island. Aurora also recently acquired Pedanios GmbH, a leading wholesale importer, exporter, and distributor of medical cannabis in the European Union (“EU”), based in Berlin, Germany. In addition, the company is the cornerstone investor with a 19.9% stake in Cann Group Limited, the only Australian company licensed to conduct research on and cultivate medical cannabis, Aurora’s common shares trade on the TSX-V under the symbol “ACB”. Visit www.auroramj.com for more information.

About Radient

Radient extracts natural compounds from a range of biological materials using its proprietary MAPTM natural product extraction technology platform which provides superior customer outcomes in terms of ingredient purity, yield, and cost. From its initial 20,000 square foot manufacturing plant in Edmonton, Alberta, Radient serves market leaders in industries that include pharmaceutical, food, beverage, natural health, personal care and biofuel markets. Visit www.radientinc.com for more information.

Business Description

Industry: Drug Manufacturers » Drug Manufacturers – Specialty & Generic    NAICS: 325411    SIC: 3741
Compare: NAS:(FLXN), OTCPK:(APHQF), NAS:(SCLN), NAS:(SCMP), NAS:(DEPO), NAS:(TLGT), NAS:(ACET), NAS:(KPTI), NYSE:(LCI), NAS:(LBIO), NAS:(ADMS), NAS:(HRTX), NAS:(AMPH), NAS:(AQXP), NAS:(TOCA), NAS:(RIGL), NAS:(TTPH), NAS:(COLL), NAS:I(NNL), NAS:(ZYNE) » details
Traded in other countries: ACB.Canada, 21P.Germany,
Headquarter Location: Canada

Aurora Cannabis Inc is a medical marijuana company. The Company is engaged in producing and distributing medical marijuana pursuant to the Marijuana for Medical Purposes Regulations.

Prescient Mining Corp was incorporated on December 21, 2006, under the laws of the Business Corporations Act. The Company is engaged in the acquisition, exploration, and development of natural resource properties.

 

Like up on FACEBOOK


logo



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )

BUZ INVESTORS PRESS RELEASE Debenture Offering Aurora Cannabis Inc. (the "Company" or "Aurora") (TSXV: ACB) (OTCQX: ACBFF) (

Aurora Cannabis Inc ACBFF OTCQX OutLook

| Calendar   | TRADE NOW | Aurora Cannabis

Aurora Cannabis Inc  ACBFF OTCQX OutLook

BUZ INVESTORS Aurora Cannabis Inc This week, another major announcement hit newswires with Aurora completing a round of financing that will bring a huge cash infusion

BUZ INVESTORS  Aurora Cannabis Inc This week, another major announcement hit newswires with Aurora completing a round of financing that will bring a huge cash infusion.

Aurora announced that it had completed its bought deal private placement (the “Offering”) of 7.0% unsecured convertible debentures (the “Debentures”) of the Company with a syndicate of investment dealers, led by Canaccord Genuity Corp., including GMP Securities L.P, Eight Capital, PI Financial Corporation, Industrial Alliance Securities Inc., and Mackie Research Capital Corporation, for gross proceeds of $75 million.

“With a cash position exceeding $160 million, we are exceptionally well positioned to execute on our expansion strategy, both nationally and internationally,” said Terry Booth, CEO. “The acquisition of Peloton in Quebec and our investment in Cann Group in Australia are the first steps in growing our footprint, and we will continue to pursue aggressively other opportunities we have identified to transform Aurora from one of the largest Canadian cannabis companies into a global leader.”

Detailed Quote

Open: 2.68
High: 2.69
Net Shares: 280,527,905
Beta: 8.099874
Prev. Close: 2.66
Low: 2.61
Market Cap: 849,445,477
VWAP: 2.637679
<trclass=””>

Dividend: N/A
Div. Frequency: N/A
Total Shares: 319,340,405
P/E Ratio: N/A
EPS: -0.07
Yield: N/A
Ex-Div Date: N/A
Escrow Shares: 38,812,500
P/B Ratio: 10.231
Exchange: TSXV

 

 

Aurora Completes $75 Million Debenture Offering

Chart | Calendar   | TRADE NOW | Aurora Cannabis Aurora Completes $75 Million Debenture Offering BUZ INVESTORS   PRESS RELEASE Debenture Offering   Aurora Cannabis Inc. (the “Company” or “Aurora”) (TSXV: ACB) (OTCQX: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) is pleased to announce that, further to its news release dated April 11, 2017, […]




Aurora Cannabis

>>>TRADE NOW<<<

Aurora Commences Sales of Cannabis Oils

Chart | Calendar   | TRADE NOW | Aurora Cannabis Aurora Commences Sales of Cannabis Oils  BUZ INVESTORS PRESS RELEASE  Cannabis Oils Aurora Cannabis Inc. (the “Company” or “Aurora”) (TSX-V: ACB) (OTCQX: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) today announced that the Company has commenced sales of a new product line of ingestible cannabis oils […]

ib) Fz(20px) Fw(b)" data-reactid="24">Income Statement

nnual Financials for Aurora Cannabis Inc.

Fiscal year is July-June. All values CAD millions. 2012 2013 2014 2015 2016 5-year trend
Sales/Revenue 1.44M
Cost of Goods Sold (COGS) incl. D&A 19,497 88,682 303 304,796 2.83M
COGS excluding D&A 19,075 88,250 2.24M
Depreciation & Amortization Expense 422 432 303 304,796 593,216
Depreciation 422 432 303 304,796 593,216
Amortization of Intangibles
Gross Income (19,497) (88,682) (303) (304,796) (1.4M)
2012 2013 2014 2015 2016 5-year trend
SG&A Expense 311,288 314,196 306,182 4.06M 6.2M
Research & Development 432,384 565,140
Other SG&A 311,288 314,196 306,182 3.63M 5.63M
Other Operating Expense
Unusual Expense 5.06M (3.09M)
EBIT after Unusual Expense (9.43M) (4.5M)
Non Operating Income/Expense (2,347)
Non-Operating Interest Income 15,025 9,389 7,855 27,639 72,777
Equity in Affiliates (Pretax)
Interest Expense 101,075 323,261 1.44M
Gross Interest Expense 101,075 323,261 1.44M
Interest Capitalized
Pretax Income (315,760) (393,489) (399,705) (9.73M) (5.87M)
Income Tax (207,708) (148,837)
Income Tax – Current Domestic (78,735)
Income Tax – Current Foreign
Income Tax – Deferred Domestic (207,708) (70,102)
Income Tax – Deferred Foreign
Income Tax Credits
Equity in Affiliates
Other After Tax Income (Expense)
Consolidated Net Income (315,760) (393,489) (399,705) (9.52M) (5.72M)
Minority Interest Expense
Net Income (315,760) (393,489) (399,705) (9.52M) (5.72M)
Extraordinaries & Discontinued Operations
Extra Items & Gain/Loss Sale Of Assets
Cumulative Effect – Accounting Chg
Discontinued Operations
Net Income After Extraordinaries (315,760) (393,489) (399,705) (9.52M) (5.72M)
Preferred Dividends
Net Income Available to Common (315,760) (393,489) (399,705) (9.52M) (5.72M)
EPS (Basic) (0.02) (0.02) (0.02) (0.12) (0.04)
Basic Shares Outstanding 15.89M 16.03M 16.15M 76.94M 128.99M
EPS (Diluted) (0.02) (0.02) (0.02) (0.12) (0.04)
Diluted Shares Outstanding 15.89M 16.03M 16.15M 76.94M 128.99M
EBITDA (330,363) (402,446) (306,182) (4.06M) (7M)

 

Like up on FACEBOOK


Ebates Coupons and Cash Back



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )




BUZ INVESTORS PRESS RELEASE Cannabis Oils Aurora Cannabis Inc. (the "Company" or "Aurora") (TSX-V: ACB) (OTCQX: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) today announced that the Company has commenced sales of a new product line

Aurora Commences Sales of Cannabis Oils

Chart | Calendar   | TRADE NOW | Aurora Cannabis

Aurora Commences Sales of Cannabis Oils

 BUZ INVESTORS PRESS RELEASE Cannabis Oils Aurora Cannabis Inc. (the "Company" or "Aurora") (TSX-V: ACB) (OTCQX: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) today announced that the Company has commenced sales of a new product line

 BUZ INVESTORS PRESS RELEASE  Cannabis Oils Aurora Cannabis Inc. (the “Company” or “Aurora”) (TSX-V: ACB) (OTCQX: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) today announced that the Company has commenced sales of a new product line of ingestible cannabis oils called Aurora Drops.

The Company’s newest offerings include three distinct product types all priced equally at a standard flat rate of $115 per bottle, or $80 per bottle for clients approved for Aurora’s compassionate pricing program:

  1. THC Drops (Sativa) – a high potency THC oil extracted from Cannabis Sativa flowers
  2. THC Drops (Indica) – a high potency THC oil extracted from Cannabis Indica flowers
  3. CBD Drops – a high potency oil extracted from Aurora’s flagship CBD strain Temple (Cannatonic)

The Company’s ingestible cannabis oils come in 30 ml glass bottles with a child resistant certified cap and dropper to allow for the easy and accurate dosing of small amounts of the high potency fluids, and are produced using CGMP compliant supercritical CO2extraction technology, as well as using an MCT carrier oil sourced from coconut oil.



Cannabis Oils

>>>TRADE NOW<<<

As with all of Aurora’s cannabis products, the test results from the independent third-party lab for each batch of ingestible oil are publicly available. Test results can be accessed online at auroramj.com/strains, or through the Aurora Mobile app, a feature rich mobile experience for iOs and Android that displays inventory tracking and restocking events, and sends push notifications for new product releases.

“The launch of our first ingestible oil products represents a major milestone, which promises to add significantly to Aurora’s top and bottom line results,” said Neil Belot, Chief Global Business Development Officer.  “We have produced a sizeable inventory of Aurora Drops for our domestic medical client base, and will be continuing to ramp up production in order to address the strong demand we anticipate for high-quality, high-margin derivative products, manufactured under the rigorous Aurora Standards regarding processes, testing, and transparency.”

The Company recently signed a Memorandum of Understanding with Radient Technologies Inc. (“RTI”) with regards to the joint development and commercialization in Canada of superior and standardized cannabinoid extracts produced using RTI’s high-throughput, terpene-preserving, proprietary extraction technology.

“The strategic partnership with RTI has the potential to be a game changer in this high-margin, high-growth segment of the cannabis market, “said Terry Booth, CEO. “If the technology works as we anticipate, Aurora will be able to produce high volumes of terpene-rich cannabis derivatives at lower costs and much shorter harvest-to-market times than any company using current industry benchmark technologies. This would give us an even stronger competitive advantage in what may well become the dominant market segment. The launch of sales is the first step in establishing our brand in the derivatives market, and we are very pleased that we are able to expand our offering to a customer base looking for alternative methods to consume cannabis.”

The companies’ technical feasibility and commercial opportunities study currently underway is proceeding well, and is expected to be completed soon.

About Aurora

Aurora’s wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed producer of medical cannabis pursuant to Health Canada’s Access to Cannabis for Medical Purposes Regulations (ACMPR). The Company operates a 55,200 square foot, state-of-the-art production facility in Mountain View County, Alberta,  is currently constructing a second 800,000 square foot production facility, known as “Aurora Sky”, at the Edmonton International Airport, and has acquired and is undertaking completion of a third 40,000 square foot production facility in Pointe Claire, Quebec, near Montreal. In addition, the company is the cornerstone investor with a 19.9% stake in Cann Group Limited, the first Australian company licensed to conduct research on and cultivate medical cannabis. Aurora’s common shares trade on the TSX-V under the symbol “ACB”.

On behalf of the Board of Directors,
AURORA CANNABIS INC.
Terry Booth, CEO

These comments contain certain “forward-looking statements” within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

The TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Aurora Cannabis Inc.

Like up on FACEBOOK


Ebates Coupons and Cash Back



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )




BUZ INVESTORS PRESS RELEASE Debenture Offering Aurora Cannabis Inc. (the "Company" or "Aurora") (TSXV: ACB) (OTCQX: ACBFF) (

Aurora Completes $75 Million Debenture Offering

Chart | Calendar   | TRADE NOW | Aurora Cannabis

Aurora Completes $75 Million Debenture Offering

BUZ INVESTORS PRESS RELEASE Debenture Offering Aurora Cannabis Inc. (the "Company" or "Aurora") (TSXV: ACB) (OTCQX: ACBFF) (Frankfurt: 21P; WKN:

BUZ INVESTORS   PRESS RELEASE Debenture Offering   Aurora Cannabis Inc. (the “Company” or “Aurora”) (TSXV: ACB) (OTCQX: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) is pleased to announce that, further to its news release dated April 11, 2017, it has completed its bought deal private placement (the “Offering”) of 7.0% unsecured convertible debentures (the “Debentures”) of the Company with a syndicate of investment dealers, led by Canaccord Genuity Corp., including GMP Securities L.P, Eight Capital, PI Financial Corporation, Industrial Alliance Securities Inc., and Mackie Research Capital Corporation, for gross proceeds of $75 million.

“With a cash position exceeding $160 million, we are exceptionally well positioned to execute on our expansion strategy, both nationally and internationally,” said Terry Booth, CEO. “The acquisition of Peloton in Quebec and our investment in Cann Group in Australia are the first steps in growing our footprint, and we will continue to pursue aggressively other opportunities we have identified to transform Aurora from one of the largest Canadian cannabis companies into a global leader.”

The Debentures are senior unsecured obligations of the Company and bear interest from the date of closing at 7.0% per annum, payable semi-annually on June 30 and December 31 of each year. The Debentures will mature on May 2, 2019 (the “Maturity Date”).



Debenture Offering

>>>TRADE NOW<<<

The Debentures are convertible at the option of the holder into common shares of the Company at any time prior to the close of business on the Maturity Date, at a conversion price of $3.29 per common share, subject to customary anti-dilution adjustments, (the “Conversion Price”). Holders converting their Debentures will receive accrued and unpaid interest thereon, up to, but excluding, the date of conversion.

If, prior to the Maturity Date, the volume-weighted average trading price of the common shares on the TSX Venture Exchange (“TSX-V”) for 10 consecutive trading days equals or exceeds $4.94, as may be adjusted from time to time, the Company may force conversion of all the then outstanding Debentures at the Conversion Price, upon giving the holders of Debenture 30 days’ prior written notice.

The Company intends to use the net proceeds of the Offering for international expansion and growth opportunities.

All securities issued in connection with the Offering, which includes certain insider participation, are subject to a four month hold period expiring September 3, 2017.

An insider of the Company was issued, directly and indirectly, Debentures in the aggregate principal amount of $300,000, which constituted a “related party transaction” within the meaning of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”). The issuance to the insider is exempt from the formal valuation and the minority shareholder approval requirements of MI 61-101, as the fair market value of the Debentures issued to and the consideration paid by such person did not exceed 25% of the Company’s market capitalization.

About Aurora

Aurora’s wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed producer of medical cannabis pursuant to Health Canada’s Access to Cannabis for Medical Purposes Regulations (“ACMPR”). The Company operates a 55,200 square foot, state-of-the-art production facility in Mountain View County, Alberta, and is currently constructing a second 800,000 square foot production facility, known as “Aurora Sky”, at the Edmonton International Airport, and has acquired, and is undertaking completion of, a third 40,000 square foot production facility in Pointe Claire, Quebec, near Montreal. In addition, the company is the cornerstone investor with a 19.9% stake in Cann Group Limited, the first Australian company licensed to conduct research on and cultivate medical cannabis. Aurora’s common shares trade on the TSX-V under the symbol “ACB”.

On behalf of the Board of Directors,
AURORA CANNABIS INC.
Terry Booth, CEO

This news release includes statements containing certain “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”). The forward-looking statements include, among other things, statements about the use of proceeds from the Offering.  Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

The TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Aurora Cannabis Inc.

 




Aurora Cannabis and Radient Technologies Provide Update on Exclusive Collaboration

Aurora Cannabis and Radient Technologies Provide Update on Exclusive Collaboration

Aurora Cannabis and Radient Technologies Provide Update on Exclusive Collaboration

Aurora Cannabis and Radient Technologies Provide Update on Exclusive Collaboration

ArrangementsVANCOUVER, Feb. 13, 2017- Aurora Cannabis Inc. (the “Company” or “Aurora”) (TSXV: ACB) (OTCQB: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) and Radient Technologies (“Radient”) (TSXV: RTI) are pleased to provide an update on their previously announced collaboration arrangements.

Project Update

As previously announced, the parties have entered into a memorandum of understanding (“MOU”) to evaluate an exclusive partnership for the Canadian market with regard to the joint development and commercialization of superior and standardized cannabinoid extracts.



Other Stories Buz Traders Follow

Aurora Cannabis

In accordance with the memorandum of understanding (“MOU”), the parties, on January 4, 2017, entered into a joint venture research agreement pursuant to which Radient and Aurora are working to confirm the effectiveness of Radient’s MAPTM technology for cannabis extraction. Initial results from the first phase of the study are encouraging. As a result, the parties have agreed to move to the second phase of the project, which includes preliminary scale-up activities. The second phase of work under the study has commenced and is expected to take approximately eight weeks.

“We are pleased with progress to date in assessing the feasibility of this potentially ground breaking extraction technology,” said Terry Booth, CEO. “The potential to substantially increase our extracts production capacity while maintaining terpene profiles would further differentiate our Company, and we are excited to be exploring this opportunity further in the coming weeks.”

Convertible Debenture

Aurora and Radient are also pleased to announce that Aurora has completed its investment in the Radient convertible debenture, announced initially on December 14, 2016 (the “Debenture”). The Debenture will have a principal amount of $2 million, a term of 2 years, bear interest at 10% per annum, and will be convertible into units of Radient at a conversion price of $0.14 per Unit. Each Unit will be comprised of one common share of Radient and one share warrant, exercisable within 24 months, for one common share of Radient at an exercise price of $0.33 per warrant. The Debenture will be repayable on demand from Aurora at any point within five months from the date of issuance.

Radient Private Placement

Additionally, Aurora intends to participate as lead investor in the private placement announced today by Radient.  The Company intends to invest up to $1.25 million in the offering. Units in the offering, priced at $0.45 each, are comprised of one common share of Radient and one half common share purchase warrant at a price of $0.70 per common share.

Denis Taschuk, President and CEO of Radient, stated “We are very encouraged with the initial positive results generated through the collective efforts of the Aurora and Radient teams, using our extraction expertise and technology for cannabis extraction, and we feel confident in meeting Aurora’s objectives. Additionally, the increasing corporate ties between Aurora and Radient and the funds raised provide us both with the resources and the ideal platform to implement our go to market strategy.”

About Aurora

Aurora’s wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed producer of medical cannabis pursuant to Health Canada’s Access to Cannabis for Medical Purposes Regulations (ACMPR). The Company operates a 55,200 square foot, state-of-the-art production facility in Mountain View County, Alberta, and is currently constructing a second 800,000 square foot, highly automated production facility at the Edmonton International Airport. Aurora trades on the TSX Venture Exchange under the symbol “ACB”.

About Radient

Radient extracts natural compounds from a range of biological materials using its proprietary MAPTM natural product extraction technology platform which provides superior customer outcomes in terms of ingredient purity, yield, and cost. From its initial 20,000 square foot manufacturing plant in Edmonton, Alberta, Radient serves market leaders in industries that include pharmaceutical, food, beverage, natural health, personal care and biofuel markets. Visit www.radientinc.com for more information.



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )




Is 2017 a Do-or-Die Year for Aurora Cannabis Stock?

Is 2017 a Do-or-Die Year for Aurora Cannabis Stock?

Is 2017 a Do-or-Die Year for Aurora Cannabis Stock?

  • Buz Investors Aurora Cannabis Stock c (CVE:ACB) has both reasons to be excited and reasons to be apprehensive about marijuana legalization prospects moving forward. Aurora Cannabis stock was down five percent on Wednesday, despite having gained six percent the day after the Canadian federal government’s task force released recommendations concerning the pot regulation process.

  • The Canadian fed’s report was largely positive for the recreational marijuana industry when it was released Tuesday. Some of the highlights include recommending that the legal age limit be set at 18 and that consumers be allowed to carry up to 30 grams in personal possession.

  • Aurora Cannabis stock was one of the biggest pot stock beneficiaries of the announcement, but has since had a regression in its share price. (Source: “Aurora Cannabis targeting 100,000 kg per year by 2017,” Financial Post, December 14, 2017.)

Aurora Cannabis Stock

Is 2017 a Do-or-Die Year for Aurora Cannabis Stock?

Aurora Cannabis Stock The Canadian fed’s report was largely positive for the recreational marijuana industry when it was released Tuesday. Some of the highlights include recommending that the legal age limit be set at 18 and that consumers be allowed to carry up to 30 grams in personal possession. Aurora Cannabis stock was one of the biggest pot stock beneficiaries of the announcement, but has since had a regression in its share price. (Source: “Aurora Cannabis targeting 100,000 kg per year by 2017,” Financial Post, December 14, 2017.)

Other Stories Buz Traders Share

Aurora Cannabis Stock 

But the company has not had all bad news. A potential boon for Aurora Cannabis stock lies in the recent growing facility that the company is constructing. The weed producer broke ground on a new 800,000 square foot growing facility that it says will have an output of 100,000 kilograms of dried product by 2018. Construction is expected to be completed by October 2017.

In a podcast interview, Aurora Cannabis CEO Terry Booth said that the major benefit to this new facility is the ability to stop and start as it sees fit. With 250,000 to 300,000 square feet of the new complex completed, the company would be able to grow marijuana in that space in late spring 2017.

 

 

Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )




Aurora Cannabis and Radient Technologies Sign MOU on Joint Venture

Aurora Cannabis and Radient Technologies Sign MOU on Joint Venture

Aurora Cannabis and Radient Technologies Sign MOU on Joint Venture

Aurora Cannabis and Radient Technologies Sign MOU on Joint Venture

VANCOUVER, Dec. 14, 2016 – Aurora Cannabis Inc. (the “Company” or “Aurora”) (TSXV: ACB) (OTCQB: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) and Radient Technologies Inc. (“Radient”) (TSXV: RTI) are pleased to announce that they have signed a memorandum of understanding (“MOU”) to evaluate an exclusive partnership for the Canadian market with regard to the joint development and commercialization of superior and standardized cannabinoid extracts. As part of the MOU, Aurora will, subject to certain conditions precedent being satisfied, invest up to $2 million into Radient by means of a convertible debenture (the “Debenture”).

Radient currently operates from a 20,000 square foot, GMP compliant, Natural Health Products Directorate (NHPD) licensed facility in Edmonton, Alberta, extracting natural ingredients for a range of industries including food and beverage, nutrition, supplements, pharmaceuticals, and cosmetics. Radient operates under strict quality controls and owns patented extraction technologies, originally developed by scientists at Environment Canada. These proprietary technologies have proven capable of producing high-quality standardized extracts with faster throughputs, improved yields, higher purities, and lower costs when compared to conventional extraction methods.

“Radient’s technology promises a significant advance in both quality and efficiency of cannabis extract production,” said Terry Booth, CEO.  “This is especially important considering global market dynamics, which point to strong demand for cannabis derivative products. Importantly, Radient’s extraction technology has also been proven to deliver superior preservation of aromatic compounds known as terpenes, which are key to the cannabis consumer experience and the Aurora Standard.”

Denis Taschuk, President and CEO of Radient, stated, “We are very excited by this potential partnership with Aurora, given their leadership position in the medical cannabis space and the exceptional quality of their products. The combination of Aurora’s recently announced capacity expansion with our proprietary high-throughput extraction technology has the potential to play an important role in meeting the fast-growing demand for quality cannabinoid extracts.”

Aurora, one of the largest licensed producers of medical cannabis under Health Canada’s Access to Cannabis for Medical Purposes Regulations (ACMPR), recently began construction on an unprecedented 800,000 square foot production facility in Leduc County, Alberta.  This facility, known as “Aurora Sky”, is anticipated to be capable of producing in excess of 100,000 kg of high-quality, low-cost marijuana per year.

Under the terms of the MOU, Aurora will fund the collaboration through the Debenture. The Debenture will have a term of 2 years, bear interest at 10% per annum and will be convertible into units (each, a “Unit”) of Radient at a conversion price of $0.14 per Unit. Each Unit will be comprised of one common share of Radient and one share warrant, exercisable within 24 months, for one common share of Radient at an exercise price of $0.33 per warrant. The issuance of the Debenture is subject to all necessary regulatory approvals, including the approval of the TSX Venture Exchange.

About Radient

Radient extracts natural compounds from a range of biological materials using it proprietary “MAPTM” natural product extraction technology platform which provides superior customer outcomes in terms of ingredient purity, yield, and cost. From its initial 20,000 square foot manufacturing plant in Edmonton, Alberta, Radient serves market leaders in industries that include pharmaceutical, food, beverage, natural health, personal care and biofuel markets. Radient trades on the TSX Venture Exchange under the symbol “RTI”. Visit www.radientinc.com for more information.